Common Warts Market
Market Insights on Common Warts covering sales outlook, demand forecast & up-to-date key trends
Common Warts Market by Diagnosis Procedure, Drug Type, Medication Class & Region – Forecast 2023–2033
Common Warts Market Snapshot (2023-2033)
The global common warts market garnered a market value of US $ 770 Million in 2023 and is expected to accumulate a market value of US$ 1100 Million by registering a CAGR of 3.6% in the forecast period 2023-2033. The worldwide common warts market was extremely strong in 2021 and is predicted to exhibit quick revenue CAGR during the forecast period. Immunosuppression is a substantial risk factor for persistent infections with Human Papilloma Viruses (HPV) and HPV-associated illness, with a frequency of 10% to 20% among school-aged children.
During the COVID pandemic, the number of immunocompromised people grew, leading to market expansion. However, the worldwide common warts market might be limited by high treatment prices and a lack of treatment availability. During the projected period, factors such as the expanding geriatric population are likely to fuel market revenue growth. The growing number of people being diagnosed with warts, owing to developments in diagnostics and HPV infections, is a key driver driving market expansion.
According to the Centers for Disease Control and Prevention, 340,000 to 360,000 people are affected by HPV-related genital warts each year. In the United States, approximately one in every 100 sexually active persons has genital warts at any one time. Moreover, the increasing frequency of warts in the general population is expected to increase the market for common warts. Furthermore, the market is expanding as a result of a rise in scientific trials conducted by various pharmaceutical companies and increased need for specific therapy to address various issues caused by common warts. These are the variables that are driving the common warts market forward.
|
Data Points |
Key Statistics |
|
Expected Market Value (2023) |
US$ 770 Million |
|
Anticipated Forecast Value (2033) |
US$ 1,100 Million |
|
Projected Growth Rate (2023-2033) |
3.6% CAGR |
Let us know your requirement to get
100% FREE customization
Common Warts Demand Analysis (2017 to 2022) Vs Market Outlook (2023 to 2033)
The global demand for common warts is projected to increase at a CAGR of 3.6% during the forecast period between 2022 and 2032, reaching a total of US$ 1,100 Million in 2032, according to a report from Future Market Insights (FMI). From 2017 to 2022, sales witnessed significant growth, registering a CAGR of 2%.
The recurrence rate of genital warts treated with topical podophyllotoxin therapy ranges between 6% and 100%. According to the Centers for Disease Control and Prevention (CDC), anogenital warts often reoccur within three months. Thus, when the recurrence incidence of warts increases, so does the use of goods and therapy, driving the market for common warts.
HPV viruses promote excessive and fast development of keratin, a hard protein found on the skin's top layer. According to the Anal Cancer Foundation, an estimated 14 million people in the United States are infected with HPV each year. According to the Centers for Disease Control and Prevention (CDC), genital warts caused by HPV afflict around 340,000 to 360,000 women and men in the United States each year. As a result, an increase in the prevalence of warts and HPV infections supports the expansion of the common warts market.
Which are Some Prominent Drivers of Common Warts Market?
The Increasing Prevalence of Common Warts and HPV infections is propelling Market Growth
People with weaker immune systems as a result of organ transplants, major illnesses such as cancer or AIDS, and atopic disorders are more likely to get warts. As a result, an increase in the number of cancer patients raises the prevalence of warts, driving the common warts market.
An increase in the number of HPV infections increases the danger of warts and, as a result, the market. According to the Anal Cancer Foundation, an estimated 14 million people in the United States are infected with HPV each year. According to the Centers for Disease Control and Prevention, genital warts caused by HPV afflict around 340,000 to 360,000 women and men in the United States each year, and they normally appear 2 to 3 months after HPV infection.
There are several treatments available for warts, but recurrences are common. A large majority of instances of genital warts do not respond to therapy and frequently reoccur, especially when infections from HPV have a protracted incubation period. As a result, an increase in the recurrence rate of common warts increases the need of products and therapy. This, in turn, is projected to fuel the market for common warts.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystWhich are the Trough Areas faced by the Common Warts Market?
The Common Warts Market is being Hampered by a Low Diagnostic Rate due to a Lack of Awareness
The expansion of the worldwide common warts market is anticipated to be impeded by a lack of knowledge of the diagnosis, which results in fewer reported instances and, as a result, less relevance for treatment choices. Although the frequency of warts is increased, the diagnostic rate in patients is low.
For example, according to the 2018 Health Protection Report, the prevalence of genital warts diagnosis among girls aged 15 to 17 in England accessing sexual health services reduced by 92% compared to 2014.
Region-Wise Insights
How will Common Warts Market Demand progress in the Asia Pacific?
Government Support to Raise Awareness about Sexually Transmitted Diseases Widening Profit Margins
Over the projection period, Asia Pacific is predicted to have high revenue CAGR. There is a significant growth in the elderly population in nations such as China, India, and others.
Moreover, the region's development rate will be enhanced due to the presence of generic producers and the expansion of healthcare facilities. These important drivers are projected to fuel market revenue growth throughout the forecast period.
Furthermore, the government support to raise awareness about sexually transmitted diseases, an increase in demand for advanced therapeutics, an increase in the prevalence of HPV infections, a rising economy, and a shift in sexual lifestyles in the area are key drivers of the Asia Pacific common warts market. As per Future Market Insights, the Asia Pacific is expected to grow at a CAGR of 3% in the assessment period 2023-2033.
How attractive are Growth Prospects for Common Warts in North America?
Increase in Pharmaceutical Firms' R&D Efforts to Accelerate Market Growth
The development of the North American market is attributable to an increase in pharmaceutical firms' R&D efforts, a high rate of treatment acceptance in healthcare facilities, and a rise in knowledge about the impacts of common warts. North America is expected to grow at a CAGR of 3.5% in the assessment period 2023-2033.
A unified Market Research Subscription Platform, built for today's disparate research needs.
Category-Wise Insights
Which Drug Type is expected to Remain Highly Sought After?
Because of Its Low Cost, Salicylic Acid Improves Clinical Outcomes
There is a growing desire for common warts therapy that leaves no scars and gives lifetime protection against HPV. As a result, businesses in the common warts market are focusing more on tissue keratolysis in order to improve patient results.
Tissue keratolysis, which uses salicylic acid, is popular in over-the-counter (OTC) drugs. This is clear since salicylic acid, a chemical destruction therapy option, is predicted to increase at an exponential rate in the common warts market throughout the projection period.
Market Competition
Key players in the common warts market are Nielsen BioSciences, Verrica Pharmaceutical, Aclaris Therapeutics, Inc., KinoPharma, Inc., pHion Therapeutics, Orgenesis, Novan, Cassopeia Pharmaceuticals, Innovax and Torii Pharmaceutical Co. Ltd.
Recent Developments
- In April 2020, Orgenesis Inc. acquired Tamir Biotechnology, Inc., including Ranpirnase, Tamir Bio's broad spectrum antiviral platform. Total stock and cash consideration was about USD 21 million based on stock valuation at the time of close.
Report Scope
|
Report Attribute |
Details |
|
Market Value in 2023 |
US$ 770 Million |
|
Market Value in 2033 |
US$ 1,100 Million |
|
Growth Rate |
CAGR of 3.6% from 2023 to 2033 |
|
Base Year for Estimation |
2022 |
|
Historical Data |
2018-2022 |
|
Forecast Period |
2023-2033 |
|
Quantitative Units |
Revenue in US$ Billion and CAGR from 2023-2033 |
|
Report Coverage |
Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
|
Segments Covered |
|
|
Regions Covered |
|
|
Key Countries Profiled |
|
|
Key Companies Profiled |
|
|
Customization |
Available Upon Request |
Key Segments Profiled in the Common Warts Market Industry Survey
Common Warts Market by Diagnosis:
- Biopsy
- Excision
Common Warts Market by Drug Type:
- Imiquimod
- Silver Nitrate
- Glutaraldehyde
- Salicylic Acid
- Formaldehydel
- Aminolevulinic Acid
Common Warts Market by Medication Class:
- Topical Retinoids
- Oral Retinoids
Common Warts Market by Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East & Africa
Frequently Asked Questions
FMI projects the global common warts market to expand at a 3.6% value CAGR by 2033
The global common warts market is estimated at a market value of US$ 770 Million
The global market for common warts treatment is expected to garner a market value of US$ 1100 Million
As per Future Market Insights, the Asia Pacific is expected to grow at a CAGR of 3% in the assessment period 2023-2033.
Nielsen BioSciences, Verrica Pharmaceutical, Aclaris Therapeutics, Inc., KinoPharma, Inc., pHion Therapeutics, Orgenesis, Novan, Cassopeia Pharmaceuticals, Innovax and Torii Pharmaceutical Co. Ltd., are some prominent Common Warts manufacturers
North America is expected to grow at a CAGR of 3.5% in the assessment period 2023-2033.
Europe is expected to grow at a CAGR of 3.3% in the assessment period 2023-2033.
The Salicylic Acid segment is expected to hold the largest market share for common warts in the forecast period 2023-2033.
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018-2022 and Forecast, 2023-2033
4.1. Historical Market Size Value (US$ Mn) Analysis, 2018-2022
4.2. Current and Future Market Size Value (US$ Mn) Projections, 2023-2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Diagnosis Procedure
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Mn) Analysis By Diagnosis Procedure, 2018-2022
5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Diagnosis Procedure, 2023-2033
5.3.1. Biopsy
5.3.2. Excision
5.4. Y-o-Y Growth Trend Analysis By Diagnosis Procedure, 2018-2022
5.5. Absolute $ Opportunity Analysis By Diagnosis Procedure, 2023-2033
6. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Drug Type
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Mn) Analysis By Drug Type, 2018-2022
6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Drug Type, 2023-2033
6.3.1. Imiquimod
6.3.2. Silver Nitrate
6.3.3. Glutaraldehyde
6.3.4. Salicylic Acid
6.3.5. Formaldehyde
6.3.6. Aminolevulinic Acid
6.4. Y-o-Y Growth Trend Analysis By Drug Type, 2018-2022
6.5. Absolute $ Opportunity Analysis By Drug Type, 2023-2033
7. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Medication Class
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Mn) Analysis By Medication Class , 2018-2022
7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Medication Class , 2023-2033
7.3.1. Topical Retinoids
7.3.2. Oral Retinoids
7.4. Y-o-Y Growth Trend Analysis By Medication Class , 2018-2022
7.5. Absolute $ Opportunity Analysis By Medication Class , 2023-2033
8. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2018-2022
8.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2023-2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. MEA
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018-2022 and Forecast 2023-2033, By Country
9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022
9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033
9.2.1. By Country
9.2.1.1. U.S.
9.2.1.2. Canada
9.2.2. By Diagnosis Procedure
9.2.3. By Drug Type
9.2.4. By Medication Class
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Diagnosis Procedure
9.3.3. By Drug Type
9.3.4. By Medication Class
9.4. Key Takeaways
10. Latin America Market Analysis 2018-2022 and Forecast 2023-2033, By Country
10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022
10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Diagnosis Procedure
10.2.3. By Drug Type
10.2.4. By Medication Class
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Diagnosis Procedure
10.3.3. By Drug Type
10.3.4. By Medication Class
10.4. Key Takeaways
11. Europe Market Analysis 2018-2022 and Forecast 2023-2033, By Country
11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022
11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. U.K.
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Diagnosis Procedure
11.2.3. By Drug Type
11.2.4. By Medication Class
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Diagnosis Procedure
11.3.3. By Drug Type
11.3.4. By Medication Class
11.4. Key Takeaways
12. Asia Pacific Market Analysis 2018-2022 and Forecast 2023-2033, By Country
12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022
12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033
12.2.1. By Country
12.2.1.1. China
12.2.1.2. Japan
12.2.1.3. South Korea
12.2.1.4. Singapore
12.2.1.5. Thailand
12.2.1.6. Indonesia
12.2.1.7. Australia
12.2.1.8. New Zealand
12.2.1.9. Rest of Asia Pacific
12.2.2. By Diagnosis Procedure
12.2.3. By Drug Type
12.2.4. By Medication Class
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Diagnosis Procedure
12.3.3. By Drug Type
12.3.4. By Medication Class
12.4. Key Takeaways
13. MEA Market Analysis 2018-2022 and Forecast 2023-2033, By Country
13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022
13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033
13.2.1. By Country
13.2.1.1. GCC Countries
13.2.1.2. South Africa
13.2.1.3. Israel
13.2.1.4. Rest of MEA
13.2.2. By Diagnosis Procedure
13.2.3. By Drug Type
13.2.4. By Medication Class
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Diagnosis Procedure
13.3.3. By Drug Type
13.3.4. By Medication Class
13.4. Key Takeaways
14. Key Countries Market Analysis
14.1. U.S.
14.1.1. Pricing Analysis
14.1.2. Market Share Analysis, 2022
14.1.2.1. By Diagnosis Procedure
14.1.2.2. By Drug Type
14.1.2.3. By Medication Class
14.2. Canada
14.2.1. Pricing Analysis
14.2.2. Market Share Analysis, 2022
14.2.2.1. By Diagnosis Procedure
14.2.2.2. By Drug Type
14.2.2.3. By Medication Class
14.3. Brazil
14.3.1. Pricing Analysis
14.3.2. Market Share Analysis, 2022
14.3.2.1. By Diagnosis Procedure
14.3.2.2. By Drug Type
14.3.2.3. By Medication Class
14.4. Mexico
14.4.1. Pricing Analysis
14.4.2. Market Share Analysis, 2022
14.4.2.1. By Diagnosis Procedure
14.4.2.2. By Drug Type
14.4.2.3. By Medication Class
14.5. Germany
14.5.1. Pricing Analysis
14.5.2. Market Share Analysis, 2022
14.5.2.1. By Diagnosis Procedure
14.5.2.2. By Drug Type
14.5.2.3. By Medication Class
14.6. U.K.
14.6.1. Pricing Analysis
14.6.2. Market Share Analysis, 2022
14.6.2.1. By Diagnosis Procedure
14.6.2.2. By Drug Type
14.6.2.3. By Medication Class
14.7. France
14.7.1. Pricing Analysis
14.7.2. Market Share Analysis, 2022
14.7.2.1. By Diagnosis Procedure
14.7.2.2. By Drug Type
14.7.2.3. By Medication Class
14.8. Spain
14.8.1. Pricing Analysis
14.8.2. Market Share Analysis, 2022
14.8.2.1. By Diagnosis Procedure
14.8.2.2. By Drug Type
14.8.2.3. By Medication Class
14.9. Italy
14.9.1. Pricing Analysis
14.9.2. Market Share Analysis, 2022
14.9.2.1. By Diagnosis Procedure
14.9.2.2. By Drug Type
14.9.2.3. By Medication Class
14.10. China
14.10.1. Pricing Analysis
14.10.2. Market Share Analysis, 2022
14.10.2.1. By Diagnosis Procedure
14.10.2.2. By Drug Type
14.10.2.3. By Medication Class
14.11. Japan
14.11.1. Pricing Analysis
14.11.2. Market Share Analysis, 2022
14.11.2.1. By Diagnosis Procedure
14.11.2.2. By Drug Type
14.11.2.3. By Medication Class
14.12. South Korea
14.12.1. Pricing Analysis
14.12.2. Market Share Analysis, 2022
14.12.2.1. By Diagnosis Procedure
14.12.2.2. By Drug Type
14.12.2.3. By Medication Class
14.13. Singapore
14.13.1. Pricing Analysis
14.13.2. Market Share Analysis, 2022
14.13.2.1. By Diagnosis Procedure
14.13.2.2. By Drug Type
14.13.2.3. By Medication Class
14.14. Thailand
14.14.1. Pricing Analysis
14.14.2. Market Share Analysis, 2022
14.14.2.1. By Diagnosis Procedure
14.14.2.2. By Drug Type
14.14.2.3. By Medication Class
14.15. Indonesia
14.15.1. Pricing Analysis
14.15.2. Market Share Analysis, 2022
14.15.2.1. By Diagnosis Procedure
14.15.2.2. By Drug Type
14.15.2.3. By Medication Class
14.16. Australia
14.16.1. Pricing Analysis
14.16.2. Market Share Analysis, 2022
14.16.2.1. By Diagnosis Procedure
14.16.2.2. By Drug Type
14.16.2.3. By Medication Class
14.17. New Zealand
14.17.1. Pricing Analysis
14.17.2. Market Share Analysis, 2022
14.17.2.1. By Diagnosis Procedure
14.17.2.2. By Drug Type
14.17.2.3. By Medication Class
14.18. GCC Countries
14.18.1. Pricing Analysis
14.18.2. Market Share Analysis, 2022
14.18.2.1. By Diagnosis Procedure
14.18.2.2. By Drug Type
14.18.2.3. By Medication Class
14.19. South Africa
14.19.1. Pricing Analysis
14.19.2. Market Share Analysis, 2022
14.19.2.1. By Diagnosis Procedure
14.19.2.2. By Drug Type
14.19.2.3. By Medication Class
14.20. Israel
14.20.1. Pricing Analysis
14.20.2. Market Share Analysis, 2022
14.20.2.1. By Diagnosis Procedure
14.20.2.2. By Drug Type
14.20.2.3. By Medication Class
15. Market Structure Analysis
15.1. Competition Dashboard
15.2. Competition Benchmarking
15.3. Market Share Analysis of Top Players
15.3.1. By Regional
15.3.2. By Diagnosis Procedure
15.3.3. By Drug Type
15.3.4. By Medication Class
16. Competition Analysis
16.1. Competition Deep Dive
16.1.1. Nielsen BioSciences
16.1.1.1. Overview
16.1.1.2. Product Portfolio
16.1.1.3. Profitability by Market Segments
16.1.1.4. Sales Footprint
16.1.1.5. Strategy Overview
16.1.1.5.1. Marketing Strategy
16.1.2. Verrica Pharmaceutical
16.1.2.1. Overview
16.1.2.2. Product Portfolio
16.1.2.3. Profitability by Market Segments
16.1.2.4. Sales Footprint
16.1.2.5. Strategy Overview
16.1.2.5.1. Marketing Strategy
16.1.3. Aclaris Therapeutics, Inc.
16.1.3.1. Overview
16.1.3.2. Product Portfolio
16.1.3.3. Profitability by Market Segments
16.1.3.4. Sales Footprint
16.1.3.5. Strategy Overview
16.1.3.5.1. Marketing Strategy
16.1.4. KinoPharma, Inc.
16.1.4.1. Overview
16.1.4.2. Product Portfolio
16.1.4.3. Profitability by Market Segments
16.1.4.4. Sales Footprint
16.1.4.5. Strategy Overview
16.1.4.5.1. Marketing Strategy
16.1.5. pHion Therapeutics
16.1.5.1. Overview
16.1.5.2. Product Portfolio
16.1.5.3. Profitability by Market Segments
16.1.5.4. Sales Footprint
16.1.5.5. Strategy Overview
16.1.5.5.1. Marketing Strategy
16.1.6. Orgenesis
16.1.6.1. Overview
16.1.6.2. Product Portfolio
16.1.6.3. Profitability by Market Segments
16.1.6.4. Sales Footprint
16.1.6.5. Strategy Overview
16.1.6.5.1. Marketing Strategy
16.1.7. Novan
16.1.7.1. Overview
16.1.7.2. Product Portfolio
16.1.7.3. Profitability by Market Segments
16.1.7.4. Sales Footprint
16.1.7.5. Strategy Overview
16.1.7.5.1. Marketing Strategy
16.1.8. Cassopeia Pharmaceuticals
16.1.8.1. Overview
16.1.8.2. Product Portfolio
16.1.8.3. Profitability by Market Segments
16.1.8.4. Sales Footprint
16.1.8.5. Strategy Overview
16.1.8.5.1. Marketing Strategy
16.1.9. Innovax
16.1.9.1. Overview
16.1.9.2. Product Portfolio
16.1.9.3. Profitability by Market Segments
16.1.9.4. Sales Footprint
16.1.9.5. Strategy Overview
16.1.9.5.1. Marketing Strategy
16.1.10. Torii Pharmaceutical Co. Ltd.
16.1.10.1. Overview
16.1.10.2. Product Portfolio
16.1.10.3. Profitability by Market Segments
16.1.10.4. Sales Footprint
16.1.10.5. Strategy Overview
16.1.10.5.1. Marketing Strategy
17. Assumptions & Acronyms Used
18. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 1: Global Market Value (US$ Mn) Forecast by Region, 2018-2033
Table 2: Global Market Value (US$ Mn) Forecast by Diagnosis Procedure, 2018-2033
Table 3: Global Market Value (US$ Mn) Forecast by Drug Type, 2018-2033
Table 4: Global Market Value (US$ Mn) Forecast by Medication Class , 2018-2033
Table 5: North America Market Value (US$ Mn) Forecast by Country, 2018-2033
Table 6: North America Market Value (US$ Mn) Forecast by Diagnosis Procedure, 2018-2033
Table 7: North America Market Value (US$ Mn) Forecast by Drug Type, 2018-2033
Table 8: North America Market Value (US$ Mn) Forecast by Medication Class , 2018-2033
Table 9: Latin America Market Value (US$ Mn) Forecast by Country, 2018-2033
Table 10: Latin America Market Value (US$ Mn) Forecast by Diagnosis Procedure, 2018-2033
Table 11: Latin America Market Value (US$ Mn) Forecast by Drug Type, 2018-2033
Table 12: Latin America Market Value (US$ Mn) Forecast by Medication Class , 2018-2033
Table 13: Europe Market Value (US$ Mn) Forecast by Country, 2018-2033
Table 14: Europe Market Value (US$ Mn) Forecast by Diagnosis Procedure, 2018-2033
Table 15: Europe Market Value (US$ Mn) Forecast by Drug Type, 2018-2033
Table 16: Europe Market Value (US$ Mn) Forecast by Medication Class , 2018-2033
Table 17: Asia Pacific Market Value (US$ Mn) Forecast by Country, 2018-2033
Table 18: Asia Pacific Market Value (US$ Mn) Forecast by Diagnosis Procedure, 2018-2033
Table 19: Asia Pacific Market Value (US$ Mn) Forecast by Drug Type, 2018-2033
Table 20: Asia Pacific Market Value (US$ Mn) Forecast by Medication Class , 2018-2033
Table 21: MEA Market Value (US$ Mn) Forecast by Country, 2018-2033
Table 22: MEA Market Value (US$ Mn) Forecast by Diagnosis Procedure, 2018-2033
Table 23: MEA Market Value (US$ Mn) Forecast by Drug Type, 2018-2033
Table 24: MEA Market Value (US$ Mn) Forecast by Medication Class , 2018-2033
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Global Market Value (US$ Mn) by Diagnosis Procedure, 2023-2033
Figure 2: Global Market Value (US$ Mn) by Drug Type, 2023-2033
Figure 3: Global Market Value (US$ Mn) by Medication Class , 2023-2033
Figure 4: Global Market Value (US$ Mn) by Region, 2023-2033
Figure 5: Global Market Value (US$ Mn) Analysis by Region, 2018-2033
Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023-2033
Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023-2033
Figure 8: Global Market Value (US$ Mn) Analysis by Diagnosis Procedure, 2018-2033
Figure 9: Global Market Value Share (%) and BPS Analysis by Diagnosis Procedure, 2023-2033
Figure 10: Global Market Y-o-Y Growth (%) Projections by Diagnosis Procedure, 2023-2033
Figure 11: Global Market Value (US$ Mn) Analysis by Drug Type, 2018-2033
Figure 12: Global Market Value Share (%) and BPS Analysis by Drug Type, 2023-2033
Figure 13: Global Market Y-o-Y Growth (%) Projections by Drug Type, 2023-2033
Figure 14: Global Market Value (US$ Mn) Analysis by Medication Class , 2018-2033
Figure 15: Global Market Value Share (%) and BPS Analysis by Medication Class , 2023-2033
Figure 16: Global Market Y-o-Y Growth (%) Projections by Medication Class , 2023-2033
Figure 17: Global Market Attractiveness by Diagnosis Procedure, 2023-2033
Figure 18: Global Market Attractiveness by Drug Type, 2023-2033
Figure 19: Global Market Attractiveness by Medication Class , 2023-2033
Figure 20: Global Market Attractiveness by Region, 2023-2033
Figure 21: North America Market Value (US$ Mn) by Diagnosis Procedure, 2023-2033
Figure 22: North America Market Value (US$ Mn) by Drug Type, 2023-2033
Figure 23: North America Market Value (US$ Mn) by Medication Class , 2023-2033
Figure 24: North America Market Value (US$ Mn) by Country, 2023-2033
Figure 25: North America Market Value (US$ Mn) Analysis by Country, 2018-2033
Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 28: North America Market Value (US$ Mn) Analysis by Diagnosis Procedure, 2018-2033
Figure 29: North America Market Value Share (%) and BPS Analysis by Diagnosis Procedure, 2023-2033
Figure 30: North America Market Y-o-Y Growth (%) Projections by Diagnosis Procedure, 2023-2033
Figure 31: North America Market Value (US$ Mn) Analysis by Drug Type, 2018-2033
Figure 32: North America Market Value Share (%) and BPS Analysis by Drug Type, 2023-2033
Figure 33: North America Market Y-o-Y Growth (%) Projections by Drug Type, 2023-2033
Figure 34: North America Market Value (US$ Mn) Analysis by Medication Class , 2018-2033
Figure 35: North America Market Value Share (%) and BPS Analysis by Medication Class , 2023-2033
Figure 36: North America Market Y-o-Y Growth (%) Projections by Medication Class , 2023-2033
Figure 37: North America Market Attractiveness by Diagnosis Procedure, 2023-2033
Figure 38: North America Market Attractiveness by Drug Type, 2023-2033
Figure 39: North America Market Attractiveness by Medication Class , 2023-2033
Figure 40: North America Market Attractiveness by Country, 2023-2033
Figure 41: Latin America Market Value (US$ Mn) by Diagnosis Procedure, 2023-2033
Figure 42: Latin America Market Value (US$ Mn) by Drug Type, 2023-2033
Figure 43: Latin America Market Value (US$ Mn) by Medication Class , 2023-2033
Figure 44: Latin America Market Value (US$ Mn) by Country, 2023-2033
Figure 45: Latin America Market Value (US$ Mn) Analysis by Country, 2018-2033
Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 48: Latin America Market Value (US$ Mn) Analysis by Diagnosis Procedure, 2018-2033
Figure 49: Latin America Market Value Share (%) and BPS Analysis by Diagnosis Procedure, 2023-2033
Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Diagnosis Procedure, 2023-2033
Figure 51: Latin America Market Value (US$ Mn) Analysis by Drug Type, 2018-2033
Figure 52: Latin America Market Value Share (%) and BPS Analysis by Drug Type, 2023-2033
Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Drug Type, 2023-2033
Figure 54: Latin America Market Value (US$ Mn) Analysis by Medication Class , 2018-2033
Figure 55: Latin America Market Value Share (%) and BPS Analysis by Medication Class , 2023-2033
Figure 56: Latin America Market Y-o-Y Growth (%) Projections by Medication Class , 2023-2033
Figure 57: Latin America Market Attractiveness by Diagnosis Procedure, 2023-2033
Figure 58: Latin America Market Attractiveness by Drug Type, 2023-2033
Figure 59: Latin America Market Attractiveness by Medication Class , 2023-2033
Figure 60: Latin America Market Attractiveness by Country, 2023-2033
Figure 61: Europe Market Value (US$ Mn) by Diagnosis Procedure, 2023-2033
Figure 62: Europe Market Value (US$ Mn) by Drug Type, 2023-2033
Figure 63: Europe Market Value (US$ Mn) by Medication Class , 2023-2033
Figure 64: Europe Market Value (US$ Mn) by Country, 2023-2033
Figure 65: Europe Market Value (US$ Mn) Analysis by Country, 2018-2033
Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 68: Europe Market Value (US$ Mn) Analysis by Diagnosis Procedure, 2018-2033
Figure 69: Europe Market Value Share (%) and BPS Analysis by Diagnosis Procedure, 2023-2033
Figure 70: Europe Market Y-o-Y Growth (%) Projections by Diagnosis Procedure, 2023-2033
Figure 71: Europe Market Value (US$ Mn) Analysis by Drug Type, 2018-2033
Figure 72: Europe Market Value Share (%) and BPS Analysis by Drug Type, 2023-2033
Figure 73: Europe Market Y-o-Y Growth (%) Projections by Drug Type, 2023-2033
Figure 74: Europe Market Value (US$ Mn) Analysis by Medication Class , 2018-2033
Figure 75: Europe Market Value Share (%) and BPS Analysis by Medication Class , 2023-2033
Figure 76: Europe Market Y-o-Y Growth (%) Projections by Medication Class , 2023-2033
Figure 77: Europe Market Attractiveness by Diagnosis Procedure, 2023-2033
Figure 78: Europe Market Attractiveness by Drug Type, 2023-2033
Figure 79: Europe Market Attractiveness by Medication Class , 2023-2033
Figure 80: Europe Market Attractiveness by Country, 2023-2033
Figure 81: Asia Pacific Market Value (US$ Mn) by Diagnosis Procedure, 2023-2033
Figure 82: Asia Pacific Market Value (US$ Mn) by Drug Type, 2023-2033
Figure 83: Asia Pacific Market Value (US$ Mn) by Medication Class , 2023-2033
Figure 84: Asia Pacific Market Value (US$ Mn) by Country, 2023-2033
Figure 85: Asia Pacific Market Value (US$ Mn) Analysis by Country, 2018-2033
Figure 86: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 87: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 88: Asia Pacific Market Value (US$ Mn) Analysis by Diagnosis Procedure, 2018-2033
Figure 89: Asia Pacific Market Value Share (%) and BPS Analysis by Diagnosis Procedure, 2023-2033
Figure 90: Asia Pacific Market Y-o-Y Growth (%) Projections by Diagnosis Procedure, 2023-2033
Figure 91: Asia Pacific Market Value (US$ Mn) Analysis by Drug Type, 2018-2033
Figure 92: Asia Pacific Market Value Share (%) and BPS Analysis by Drug Type, 2023-2033
Figure 93: Asia Pacific Market Y-o-Y Growth (%) Projections by Drug Type, 2023-2033
Figure 94: Asia Pacific Market Value (US$ Mn) Analysis by Medication Class , 2018-2033
Figure 95: Asia Pacific Market Value Share (%) and BPS Analysis by Medication Class , 2023-2033
Figure 96: Asia Pacific Market Y-o-Y Growth (%) Projections by Medication Class , 2023-2033
Figure 97: Asia Pacific Market Attractiveness by Diagnosis Procedure, 2023-2033
Figure 98: Asia Pacific Market Attractiveness by Drug Type, 2023-2033
Figure 99: Asia Pacific Market Attractiveness by Medication Class , 2023-2033
Figure 100: Asia Pacific Market Attractiveness by Country, 2023-2033
Figure 101: MEA Market Value (US$ Mn) by Diagnosis Procedure, 2023-2033
Figure 102: MEA Market Value (US$ Mn) by Drug Type, 2023-2033
Figure 103: MEA Market Value (US$ Mn) by Medication Class , 2023-2033
Figure 104: MEA Market Value (US$ Mn) by Country, 2023-2033
Figure 105: MEA Market Value (US$ Mn) Analysis by Country, 2018-2033
Figure 106: MEA Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 107: MEA Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 108: MEA Market Value (US$ Mn) Analysis by Diagnosis Procedure, 2018-2033
Figure 109: MEA Market Value Share (%) and BPS Analysis by Diagnosis Procedure, 2023-2033
Figure 110: MEA Market Y-o-Y Growth (%) Projections by Diagnosis Procedure, 2023-2033
Figure 111: MEA Market Value (US$ Mn) Analysis by Drug Type, 2018-2033
Figure 112: MEA Market Value Share (%) and BPS Analysis by Drug Type, 2023-2033
Figure 113: MEA Market Y-o-Y Growth (%) Projections by Drug Type, 2023-2033
Figure 114: MEA Market Value (US$ Mn) Analysis by Medication Class , 2018-2033
Figure 115: MEA Market Value Share (%) and BPS Analysis by Medication Class , 2023-2033
Figure 116: MEA Market Y-o-Y Growth (%) Projections by Medication Class , 2023-2033
Figure 117: MEA Market Attractiveness by Diagnosis Procedure, 2023-2033
Figure 118: MEA Market Attractiveness by Drug Type, 2023-2033
Figure 119: MEA Market Attractiveness by Medication Class , 2023-2033
Figure 120: MEA Market Attractiveness by Country, 2023-2033
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
